How Much Does Zepbound Cost in Arkansas in 2026?

Zepbound Retail Pricing in Arkansas

Brand-name Zepbound carries a manufacturer list price of $1,059 per month across all dose strengths, and Arkansas retail pharmacies mirror this figure closely. Walgreens, CVS, and independent pharmacies in Little Rock, Fayetteville, and Jonesboro all price within a few dollars of the national list.

This flat pricing means the cost does not increase as patients titrate from the starting 2.5 mg dose to higher maintenance doses of 10 mg, 12.5 mg, or 15 mg. Eli Lilly set this single-price structure when the FDA approved Zepbound in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity [1].

The clinical rationale behind this price reflects the drug's trial data. In SURMOUNT-1 (N=2,539), participants receiving tirzepatide 15 mg lost 22.5% of body weight at 72 weeks compared to 3.1% with placebo [2]. That degree of weight reduction exceeded what earlier GLP-1 receptor agonists achieved in comparable trials. The dual GIP/GLP-1 mechanism targets two incretin pathways simultaneously, producing greater appetite suppression and improved glycemic control than single-receptor agents alone.

For patients paying cash at Arkansas pharmacies, GoodRx and RxSaver coupons occasionally bring the price to $950 to $1,020, but discounts this small rarely change the affordability equation. The real savings come through insurance coverage or alternative sourcing, discussed below.

Arkansas Insurance Coverage for Zepbound

Commercial insurance plans in Arkansas vary widely in their Zepbound coverage. Large employer-sponsored plans from Blue Cross Blue Shield of Arkansas, QualChoice, and Ambetter frequently include GLP-1 medications on their formularies, but almost all require prior authorization. The approval criteria typically include a documented BMI ≥30 (or ≥27 with a qualifying comorbidity such as type 2 diabetes, hypertension, or dyslipidemia), failure of at least one structured weight-management program, and prescriber attestation that the patient will continue lifestyle modifications.

Copays for approved patients range from $25 to $150 on preferred tiers. Non-preferred placement pushes copays to $250 to $550 per month. Some plans impose step therapy, requiring a trial of an older agent like liraglutide 3 mg (Saxenda) or semaglutide 2.4 mg (Wegovy) before authorizing Zepbound.

According to the Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity, anti-obesity medications should be considered for patients who do not achieve sufficient weight loss with lifestyle intervention alone, and insurance barriers to these medications represent a significant access problem [3]. Arkansas patients who receive an initial denial should file a formal appeal. Internal data from telehealth providers suggest that roughly 40% to 60% of Zepbound prior authorization denials are overturned on first appeal when supported by comprehensive clinical documentation.

A practical step: ask your prescriber's office for the specific denial reason code. Denials based on missing documentation (rather than outright exclusion) are the easiest to reverse.

Arkansas Medicaid and Zepbound

Arkansas Medicaid provides limited coverage for Zepbound, requiring prior authorization before it will reimburse the prescription. The state's preferred drug list historically categorizes weight-management medications as non-preferred, adding extra paperwork for prescribers and longer wait times for patients.

To qualify under Arkansas Medicaid, patients generally need to demonstrate a BMI ≥30 with at least one obesity-related condition such as type 2 diabetes, obstructive sleep apnea, or cardiovascular disease [4]. A 2023 study in the Journal of the American Heart Association found that tirzepatide reduced major adverse cardiovascular event risk markers alongside weight loss, which strengthens the medical necessity argument for Medicaid coverage requests.

Arkansas expanded Medicaid through the ARHOME program (Arkansas Health and Opportunity for Me), which covers adults up to 138% of the federal poverty level. ARHOME enrollees face the same prior authorization requirements as traditional Medicaid beneficiaries. The program does not have a separate formulary for weight-management drugs.

Patients on Arkansas Medicaid cannot combine the Eli Lilly savings card with their coverage. Federal anti-kickback statutes prohibit manufacturer copay assistance for government-funded insurance programs, including Medicaid, Medicare, and TRICARE. This restriction makes compounded tirzepatide an important alternative for Medicaid patients whose prior authorization is denied.

Compounded Tirzepatide in Arkansas

Compounded tirzepatide is available in Arkansas through licensed 503A compounding pharmacies. These pharmacies prepare patient-specific prescriptions under state Board of Pharmacy oversight, and the typical cost runs around $249 per month. That is roughly 76% less than brand-name Zepbound.

The legal basis for compounding rests on the FDA's guidance on 503A compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act [5]. A licensed pharmacist may compound a drug when a valid patient-specific prescription exists and the compounded product is not essentially a copy of a commercially available drug. Tirzepatide compounding has operated in a regulatory gray zone because the drug was on the FDA shortage list from late 2023 through portions of 2024 and 2025, which temporarily broadened compounding eligibility [6].

As of early 2026, patients considering compounded tirzepatide in Arkansas should verify two things. First, confirm that the pharmacy holds a current Arkansas Board of Pharmacy license for compounding. Second, ask whether the pharmacy conducts third-party potency and sterility testing on each batch. Reputable 503A pharmacies will provide certificates of analysis on request.

Several telehealth platforms operating in Arkansas connect patients with prescribers who can write compounded tirzepatide prescriptions. These platforms typically charge $149 to $349 per month for the medication plus a monthly or quarterly consultation fee of $50 to $99. Total out-of-pocket costs through this route generally fall between $249 and $400 per month, still well below the $1,059 brand-name price.

"Compounded GLP-1 receptor agonists can serve as an interim option for patients who face insurance barriers, but prescribers should verify the compounding pharmacy's quality standards and regulatory compliance," stated the American Association of Clinical Endocrinology's 2023 consensus statement on obesity pharmacotherapy [7].

The Eli Lilly Savings Card: How It Works in Arkansas

Eli Lilly offers a manufacturer savings card for Zepbound that reduces out-of-pocket costs for commercially insured patients. The card covers up to $563 per month in copay assistance, bringing many patients' costs down to $25 per fill.

Eligibility requirements are straightforward. The patient must have commercial (private) insurance. They cannot be enrolled in a government-funded plan (Medicare, Medicaid, TRICARE, or VA). The card is valid for up to 13 fills within a 24-month activation period.

For uninsured Arkansas patients, Lilly introduced single-dose vials at a lower price point. The 2.5 mg and 5 mg single-dose vials are available for $399 per month through the LillyDirect program, which ships medication directly to patients after a qualifying telehealth visit. This option bypasses both insurance and retail pharmacy pricing, though it is only available at the two lowest dose strengths.

Arkansas patients can activate the savings card at zepbound.lilly.com or by calling the number on the Zepbound packaging [1]. Activation takes approximately five minutes, and the card can be used at any Arkansas pharmacy that accepts commercial insurance.

Telehealth Access to Zepbound in Arkansas

Arkansas permits telehealth prescribing of Zepbound without an in-person visit. The Arkansas State Medical Board allows physicians and advanced practice providers to prescribe controlled and non-controlled medications via synchronous audio-video telemedicine encounters, provided they establish a valid patient-provider relationship during the consultation.

Several national telehealth platforms serve Arkansas patients for GLP-1 prescriptions. Pricing models vary. Some charge a flat monthly fee that bundles the consultation, prescription management, and medication. Others separate the prescriber visit fee from the medication cost.

A typical telehealth pathway in Arkansas looks like this: the patient completes an intake form with medical history and current medications, has a video consultation with a licensed prescriber, receives a prescription sent electronically to either a retail pharmacy or a compounding pharmacy, and begins treatment with ongoing monthly or quarterly check-ins.

The CDC's 2024 report on telehealth utilization noted that telehealth visits for obesity management increased 340% between 2019 and 2023, driven primarily by GLP-1 receptor agonist prescribing [8]. Arkansas's rural geography makes telehealth access particularly relevant. Patients in the Delta region, the Ozarks, and other areas distant from endocrinology or obesity medicine specialists can access Zepbound prescriptions without traveling to Little Rock or Fayetteville.

One caveat: not all telehealth prescribers will write for brand-name Zepbound to be filled at a retail pharmacy, because insurance prior authorization often requires documentation that some telehealth platforms are not equipped to provide. Patients who want brand-name Zepbound covered by insurance may need a primary care physician or specialist to handle the prior authorization process.

Cost Comparison: Brand vs. Compounded vs. Savings Card

Understanding the price differences across sourcing options helps Arkansas patients make informed decisions. The table below summarizes the main pathways.

Brand-name Zepbound at retail without insurance costs $1,059 per month at any dose. With commercial insurance and the Lilly savings card, many patients pay $25 to $150 per month depending on formulary tier. Without the savings card but with insurance, copays typically range from $50 to $550.

Compounded tirzepatide through a 503A pharmacy averages $249 per month, with some pharmacies charging $199 for lower doses and up to $349 for the highest concentrations. The LillyDirect single-dose vial program runs $399 per month but is restricted to the 2.5 mg and 5 mg doses.

For patients who have tried and failed other weight-management medications, some Arkansas providers have successfully argued for insurance exceptions using the SURMOUNT trial data. In SURMOUNT-1, the 15 mg dose group achieved a mean weight loss of 22.5% at 72 weeks, and 63% of participants in that group lost at least 20% of their body weight, compared to 1.3% in the placebo arm [2]. These numbers can strengthen a letter of medical necessity, particularly when the patient has documented failure on semaglutide or liraglutide.

"The magnitude of weight loss achieved with tirzepatide in SURMOUNT-1 sets a new benchmark for pharmacological obesity treatment," wrote Dr. Ania Jastreboff and colleagues in the New England Journal of Medicine [2].

What to Do If You Are Denied Coverage in Arkansas

Prior authorization denials for Zepbound are common across all Arkansas payers. A structured appeal process increases the odds of reversal.

Step one: request the written denial letter, which must include the specific reason for denial and the clinical criteria the plan used. Step two: have your prescriber write a letter of medical necessity citing your BMI, weight-related comorbidities, prior treatment failures, and relevant trial data (SURMOUNT-1 and SURMOUNT-2 are the most cited). Step three: submit the appeal within the timeframe specified in your plan documents, which is typically 30 to 60 days in Arkansas.

If the internal appeal fails, Arkansas patients have the right to request an external review through the Arkansas Insurance Department. External reviews are conducted by independent physicians who are not affiliated with the insurance company. The Arkansas Insurance Department oversees this process and provides instructions on its website [9].

Patients with employer-sponsored plans governed by ERISA (the Employee Retirement Income Security Act) follow federal appeal procedures rather than state ones. ERISA plans must provide two levels of internal appeal before the patient can pursue external review or legal action.

Arkansas-Specific Savings Strategies

Patients in Arkansas can reduce Zepbound costs through several approaches beyond insurance and the manufacturer savings card.

Patient assistance programs from Eli Lilly may cover the full cost of Zepbound for uninsured patients with household incomes below 400% of the federal poverty level ($62,400 for an individual in 2026). The application requires proof of income, a valid prescription, and documentation that the patient does not have prescription drug coverage.

Arkansas's major health systems, including UAMS (University of Arkansas for Medical Sciences), Baptist Health, and CHI St. Vincent, have obesity medicine programs that may offer bundled pricing for visits plus medication management. UAMS's weight management clinic in Little Rock has prescribers experienced with GLP-1 prior authorization processes, which can reduce delays.

Pharmacy discount aggregators such as GoodRx, RxSaver, and SingleCare occasionally post Arkansas-specific prices $30 to $100 below list price. These discounts cannot be combined with insurance or the Lilly savings card, making them most useful for cash-pay patients who do not qualify for other assistance.

For patients weighing compounded tirzepatide, the FDA recommends verifying that the compounding pharmacy is licensed in the patient's state and that it operates under appropriate quality controls [5]. Arkansas patients should confirm the pharmacy's license status through the Arkansas State Board of Pharmacy.

Starting dose for Zepbound is 2.5 mg weekly for four weeks, then 5 mg weekly, with titration to 10 mg, 12.5 mg, or 15 mg based on tolerability and clinical response per the FDA-approved prescribing information [1].